Role of O-GlcNAc-ylation on tumor progression
O-GlcNAc 基化在肿瘤进展中的作用
基本信息
- 批准号:10589810
- 负责人:
- 金额:$ 33.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-10 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:ABCB1 geneAntineoplastic AgentsAttenuatedBiological ModelsBiological ProcessBreast Cancer CellBreast Cancer ModelCarbohydratesCell Cycle ProgressionCell ProliferationCellsCharacteristicsChemicalsChemoresistanceDNA RepairDNA Repair GeneDiabetes MellitusDietEmbryonic DevelopmentErinaceidaeEventGLI Family ProteinGLI geneGeneticGenetic TranscriptionGlucoseHomeostasisHumanHydroxyl RadicalHyperglycemiaImmuneImpairmentInvestigationLicensingLinkMalignant NeoplasmsMammary NeoplasmsMass Spectrum AnalysisMetabolicMetabolismMicroclimateModelingModificationMolecularNeurodegenerative DisordersNormal tissue morphologyNutritional statusOutcomePathway interactionsPhenotypeProcessProteinsProteomicsReportingResearch DesignRoleSerineSideSignal PathwaySignal TransductionSiteStructureTestingThreonineTissuesTumor Cell InvasionUp-Regulationcancer cellcancer typechemotherapeutic agentcytotoxicglucose uptakemalignant breast neoplasmmouse modelneoplastic cellnovelpatient derived xenograft modelprogramsresilienceresponsesmall molecule inhibitorsmoothened signaling pathwaysuccesssugartooltranscription factortriple-negative invasive breast carcinomatumortumor progression
项目摘要
Abstract
O-linked ß-N-acetylglucosamine (O-GlcNAc) is a sugar attachment to the side chain hydroxyl of a serine or
threonine residue on proteins. O-GlcNAcylation controls key signaling and biological processes such as signal
transduction, transcription, cell cycle progression, and metabolism. Perturbations in O-GlcNAc homeostasis
have been linked with diabetes, cancer, and neurodegenerative diseases. Increased glucose levels channel flux
through the Hexoseamine Biosynthetic Pathway (HBP), culminating in increased O-GlcNAc levels.
The activity of HBP and consequently cellular O-GlcNAc-ylation are elevated in several cancer types, including
breast cancer. We recently reported that inhibiting HBP activity significantly decreased the invasive phenotype
of breast tumor cells. We surmised that abundance of glucose, a readily-metabolizable carbohydrate, will drive
flux through HBP, resulting in enrichment of a portfolio of proteins that are modified by O-GlcNAc-ylation. Using
unbiased proteomics analysis, we identified that elevated glucose culture conditions enrich for O-GlcNAc-
modified GLI proteins, transcription factors of the Hedgehog (Hh) pathway. Importantly, we identified that in
elevated glucose conditions, O-GlcNAc-modification of GLI exacerbates Hh/GLI activity; and inhibiting HBP
mitigated this effect. We hypothesize that HBP-directed O-GlcNAc-ylation fundamentally programs invasive and
chemoresistant attributes in tumor cells through activating Hh/GLI signaling.
In Aim 1 we will determine the molecular underpinnings of HBP-directed O-GlcNAc-ylation of GLI. We will
determine the causes and consequences of GLI O-GlcNAc-ylation. We will first identify engagement of the HBP
in O-GlcNAc-modification of GLI proteins. Next, we will undertake investigations to identify establish the
mechanistic basis of how HBP signaling engages O-GlcNAc-modified GLI to program invasive and
chemoresistant attributes in tumor cells.
In Aim 2 we will evaluate the impact of an elevated O-GlcNAc landscape on molecular and cellular attributes of
the mammary tumor and the associated immune microclimate using two distinct and complementary syngeneic
mouse models of mammary cancer. To enrich the relevance, we will also evaluate human TNBC and PDX model
systems. We will test if inhibiting GLI activity, in the context of elevated O-GlcNAc, uncouples the influence of O-
GlcNAc-ylation on invasive and chemoresistant attributes of mammary tumor cells.
Relevance: Our proposed studies are structured to systematically investigate how O-GlcNAc-driven metabolic
reprogramming in cancer cells connects at the molecular level to aberrantly activate Hh/GLI signaling. The
cumulative outcomes will create mechanistic understanding of how O-GlcNAc-ylation programs tumor invasion,
progression and response to anti-neoplastics.
摘要
O-连接-N-乙酰氨基葡萄糖(O-GlcNAc)是一种附着在丝氨酸或
蛋白质上的苏氨酸残基。O-GlcN酰化控制关键信号和生物过程,如信号
转导、转录、细胞周期进程和新陈代谢。O-GlcNAc动态平衡中的扰动
与糖尿病、癌症和神经退行性疾病有关。血糖水平升高通道流量
通过己糖胺生物合成途径(HBP),最终导致O-GlcNAc水平增加。
在几种癌症类型中,HBP的活性以及由此导致的细胞O-GlcNAc甲基化水平升高,包括
乳腺癌。我们最近报道,抑制HBP活性显著降低了侵袭性表型
乳腺肿瘤细胞。我们推测,丰富的葡萄糖,一种易代谢的碳水化合物,将推动
通过HBP的通量,导致通过O-GlcNAc修饰的蛋白质组合的丰富。vbl.使用
无偏蛋白质组学分析,我们发现高糖培养条件富含O-GlcNAc-
修饰的GLI蛋白,Hedgehog(HH)途径的转录因子。重要的是,我们在
高糖条件下,O-GlcNAc修饰GLI加剧HH/GLI活性;并抑制HBP
减轻了这一影响。我们假设HBP引导的O-GlcNAc基化从根本上编程侵袭性和
通过激活HH/GLI信号使肿瘤细胞具有化疗耐药特性。
在目标1中,我们将确定HBP指导的GLI的O-GlcNAc基化的分子基础。我们会
确定GLiO-GlcNAc甲基化的原因和后果。我们将首先确定HBP的参与度
GLI蛋白的O-GlcNAc修饰。接下来,我们将进行调查,以确定
HBP信号如何参与O-GlcNAc修饰的GLI来编程侵袭性和
肿瘤细胞的化疗耐药属性。
在目标2中,我们将评估升高的O-GlcNAc景观对细胞的分子和细胞属性的影响
两个不同互补的同源基因与乳腺肿瘤及其相关免疫小气候
小鼠乳腺癌模型。为了丰富相关性,我们还将评估人类TNBC和PDX模型
系统。我们将测试在O-GlcNAc升高的情况下,抑制GLI活性是否解偶联O-
乳腺肿瘤细胞侵袭和耐药属性的GlcNAc甲基化。
相关性:我们建议的研究旨在系统地研究O-GlcNAc如何驱动代谢
癌细胞中的重编程在分子水平上连接,以异常激活HH/GLI信号。这个
累积的结果将建立对O-GlcNAc甲基化如何规划肿瘤侵袭的机械性理解,
抗肿瘤药物的进展和反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lalita A. Shevde其他文献
Multi-faceted role of HSP40 in cancer
- DOI:
10.1007/s10585-009-9255-x - 发表时间:
2009-04-02 - 期刊:
- 影响因子:3.200
- 作者:
Aparna Mitra;Lalita A. Shevde;Rajeev S. Samant - 通讯作者:
Rajeev S. Samant
Emerging role of nuclear protein 1 (NUPR1) in cancer biology
- DOI:
10.1007/s10555-009-9183-x - 发表时间:
2009-01-20 - 期刊:
- 影响因子:8.700
- 作者:
Uttio Roy Chowdhury;Rajeev S. Samant;Oystein Fodstad;Lalita A. Shevde - 通讯作者:
Lalita A. Shevde
Informing the new developments and future of cancer immunotherapy
- DOI:
10.1007/s10555-021-09967-1 - 发表时间:
2021-05-18 - 期刊:
- 影响因子:8.700
- 作者:
Atul Kumar;Courtney A. Swain;Lalita A. Shevde - 通讯作者:
Lalita A. Shevde
Erratum to: ‘Hedgehog signaling: modulation of cancer properties and tumor microenvironment’
- DOI:
10.1186/s12943-016-0522-6 - 发表时间:
2016-05-11 - 期刊:
- 影响因子:33.900
- 作者:
Ann Hanna;Lalita A. Shevde - 通讯作者:
Lalita A. Shevde
The metastatic cascade through the lens of therapeutic inhibition
通过治疗性抑制视角看转移级联
- DOI:
10.1016/j.xcrm.2024.101872 - 发表时间:
2025-01-21 - 期刊:
- 影响因子:10.600
- 作者:
Ian Miranda;Nusrat Jahan;Lalita A. Shevde - 通讯作者:
Lalita A. Shevde
Lalita A. Shevde的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lalita A. Shevde', 18)}}的其他基金
Role of O-GlcNAc-ylation on tumor progression
O-GlcNAc 基化在肿瘤进展中的作用
- 批准号:
10444126 - 财政年份:2022
- 资助金额:
$ 33.29万 - 项目类别:
Roadmap for America's Cancer Explorers for the 21st Century (Race 21)
21 世纪美国癌症探索者路线图(第 21 场比赛)
- 批准号:
10252847 - 财政年份:2020
- 资助金额:
$ 33.29万 - 项目类别:
Roadmap for America's Cancer Explorers for the 21st Century (Race 21)
21 世纪美国癌症探索者路线图(第 21 场比赛)
- 批准号:
10478045 - 财政年份:2020
- 资助金额:
$ 33.29万 - 项目类别:
Roadmap for America's Cancer Explorers for the 21st Century (Race 21)
21 世纪美国癌症探索者路线图(第 21 场比赛)
- 批准号:
10023708 - 财政年份:2020
- 资助金额:
$ 33.29万 - 项目类别:
Molecular determinants of breast cancer malignancy
乳腺癌恶性肿瘤的分子决定因素
- 批准号:
8458999 - 财政年份:2011
- 资助金额:
$ 33.29万 - 项目类别:
Molecular determinants of breast cancer malignancy
乳腺癌恶性肿瘤的分子决定因素
- 批准号:
8653835 - 财政年份:2011
- 资助金额:
$ 33.29万 - 项目类别:
Molecular determinants of breast cancer malignancy
乳腺癌恶性肿瘤的分子决定因素
- 批准号:
8261842 - 财政年份:2011
- 资助金额:
$ 33.29万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 33.29万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 33.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 33.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 33.29万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 33.29万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 33.29万 - 项目类别:














{{item.name}}会员




